PhIII fail in overall survival measure clouds Ipsen's expansion plans for cancer drug Onivyde

Ipsen’s grand plan to open up new markets for the cancer drug Onivyde has hit a snag. Its Phase III trial testing the therapy in small cell lung cancer failed the primary endpoint on overall survival, casting a shadow on its regulatory prospects.